NCT06984510 Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
| NCT ID | NCT06984510 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ningbo No. 1 Hospital |
| Condition | Type 2 Diabetes Mellitus (T2DM) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,720 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,720 participants in total. It began in 2025-04-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.
Eligibility Criteria
Inclusion Criteria: 1. Abdominal ultrasound data available in annual health check-up records 2. At least one of the following five metabolic indicators recorded annually: (1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c) Exclusion Criteria: 1. Age \<20 or \>90 years 2. Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection) 3. Type 2 diabetes mellitus at baseline 4. Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06984510 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 90 Years, studying Type 2 Diabetes Mellitus (T2DM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06984510 currently recruiting?
Yes, NCT06984510 is actively recruiting participants. Contact the research team at xulei22@163.com for enrollment information.
Where is the NCT06984510 trial being conducted?
This trial is being conducted at Ningbo, China.
Who is sponsoring the NCT06984510 clinical trial?
NCT06984510 is sponsored by Ningbo No. 1 Hospital. The trial plans to enroll 2,720 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.